Improved prediction of response to treatment in breast cancer

Agendia has announced the publication of study results for BluePrint, its 80-gene proprietary molecular subtyping test, in the journal Nature Breast Cancer.

It is well known that a significant subset of patients diagnosed with early-stage oestrogen receptor (ER)-positive (ER+) breast cancer appear to respond poorly to standard anti-oestrogen therapy and may benefit significantly by the addition of chemotherapy. This latest study suggests that use of BluePrint can more precisely predict tumour response to treatment and clinical outcome.

The study entitled Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers sought to conduct a molecular analysis and clinical follow-up of patients who were reclassified as ER+ basal-type (n=91) in the Neoadjuvant Breast Registry Symphony Trial (NBRST; n=1072). The results of the analysis showed that ER+ basal-type patients revealed missing sections from the messenger RNA (mRNA) for the ER gene ESR1, rendering the translated ER protein non-functional; ER+ basal-type patients experienced a far higher rate of pCR with neoadjuvant chemotherapy than did ER+ luminal patients (34% vs. 5%); and three-year outcomes were comparable to triple-negative patients.


Other news

Visualise No Malaria

Upcoming Events

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

Ist International Blizard/QMUL Tuberculosis Symposium

Bearsted Lecture Theatre, Alexandra Wing, Queen Mary University of London - Whitechapel
26-27 June 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Apr 2019

Reducing exposure to antimicrobial agents

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.